At the first appointment with a local surgeon in Virginia Beach in 2014, Ralph and his wife Brenda were told he had two to three years to live. They left that appointment in shock, disbelief, and tears. Within 2 weeks, Ralph was a patient at Johns Hopkins where he had his right kidney removed and a partial lung resection.
Three months later, in September 2014, Ralph met Dr. Hans Hammers, a kidney cancer specialist and researcher at Johns Hopkins, now at UT Southwestern Dallas. Ralph’s first post-op scan revealed two cancerous nodules in his lungs. The cancer was back.
Dr. Hammers then told the Knapps about a randomized trial that involved two immunotherapy drugs which had shown success in earlier clinical trials. After weighing his options, Ralph decided to wait for the trial to open. After 5 agonizing months of no treatment, he was randomized to the standard of care drug. After six weeks, his tumors seemed to explode on this drug, and Dr. Hammers immediately put him on an off-label use drug. This drug halted the cancer progression, but it made Ralph feel terrible. While on that drug, Ralph continued to research his next treatment option. He read a blog on Smart Patients about a new trial Dr. Hammers wanted to start at Johns Hopkins with the same immunotherapy drugs, plus high dose radiation. However, he needed funding to make this study happen.
Ralph and Brenda learned that Dr. Hammers had secured millions of dollars in drugs through BMS and was trying to get funding from various departments at Johns Hopkins. The Knapps let him know that if he needed them, they would help with funding. On June 9, 2015, (one year to the date of Ralph’s diagnosis), Dr. Hammers called and said he could use help. Within a month, more than 100 of the Knapps’ friends, family, and business associates came together and raised $300,000 for the RADAX clinical trial. This made treatment through a clinical trial possible for 25 advanced kidney cancer patients, including Ralph.
Ralph realized his survival, as well as that of 60,000 other newly-diagnosed kidney cancer patients, depended on cutting-edge research. After a thorough search for a private funding vehicle for kidney cancer research, it was obvious there was a need for a national nonprofit to fund kidney cancer research. In July 2016, the Knapps co-founded the Kidney Cancer Coalition, which they later merged with KCAN to form KidneyCAN. Raising funds for research and clinical trials and to accelerate cures for kidney cancer became Ralph’s hope and passion.
Ralph continued fighting cancer and fighting for research funding until his death in March of 2022. Ralph’s legacy is KidneyCAN, and his work to raise awareness and research funding has created hope and opportunity for kidney cancer patients all over the world. We hope you will read more about Ralph’s life and work.